Project: Xcorporeal XCR-6
XCR-6 Dialysis Platform for Self-Directed Kidney Hemodialysis
Syncroness is excited to be involved in the development of the XCR-6, a ground breaking new device with the potential of improving the quality of life for millions. LOS ANGELES--(BUSINESS WIRE)--Nov. 12, 2008--Xcorporeal, Inc. (AMEX:XCR) announced today the XCR-6 Dialysis Platform for self-directed kidney hemodialysis. The XCR-6 will be the smallest, lightest, and easiest to use dialysis machine ever conceived, using Xcorporeal's proprietary closed loop, regenerated dialysate technology platform. The Company is currently preparing for unattended/home use clinical trials of the XCR-6 in anticipation of commercialization in the near future. The XCR-6 was developed through extensive research and represents a significant improvement compared with equipment currently utilized by patients suffering from chronic renal failure. The technology will, for the first time, allow dialysis providers to "bring the therapy to the patient" because the XCR-6 uses an extremely small amount of tap water; requires no special plumbing or water processing plants; runs on standard household electricity; is the size and weight of a small household appliance; is easy to learn and use as all tubing is integrated into a single proprietary cassette that snaps into place with one hand and retains all fluids within the disposable cassette, facilitating clean up. The Company estimates that the home hemodialysis market represents a multi-billion dollar revenue opportunity. Xcorporeal, Inc. is a medical device company developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs. The platform leads to three initial products: a Portable Artificial Kidney (PAK) for hospital based Renal Replacement Therapy, the XCR-6 for home hemodialysis, and a Wearable Artificial Kidney (WAK) for continuous ambulatory hemodialysis. 
.
|